中国鼻咽癌分期2017版(2008鼻咽癌分期修订专家共识)

准确的肿瘤临床分期是指导治疗、判断预后以及学术交流的基础。自2009年国内推广使用“鼻咽癌2008分期”以来,各肿瘤中心加强了合作和交流,促进了多中心研究和分期研究的发展。2017年7月1日,中国鼻咽癌临床分期工作委员会在福建南平召开了中国鼻咽癌分期修订工作会议,国内各位专家基于循证医学进行充分地讨论和沟通,并达成共识,一致认为采纳了鼻咽癌中国2008分期和UICC/AJCC分期第7版各自优势基础上做了更新的UICC/AJCC分期第8版较为合理,中国2008分期的修订应参照UICC/AJCC第8版分期标准,以制定国际统一的分期标准。因此,推荐新的中国鼻咽癌分期2017版与UICC/AJCC分期第8版保持一致。

The 2017 edition for staging of nasopharyngeal carcinoma in China ( The Chinese 2008 expert consensus on staging revision of nasopharyngeal carcinoma )

The staging of malignant tumors is a fundamental component of treatment selection, prognosis prediction and academic exchange. As"Chinese 2008 staging for nasopharyngeal carcinoma ( NPC)"was widely adopted in China from 2009, more and more coordination and exchange of information has been carried out between treatment centers, which has promoted the development of multicenter clinical trials and staging studies. On July 1, 2017, an expert consensus conference was held by the Chinese Committee for Staging of NPC to discuss the revision of Chinese 2008 staging for NPC in Nanping City, Fujian Province. After a full discussion and communication according to evidence-based medicine, a consensus was made. The 8th edition UICC/AJCC staging system for NPC was more rational because it had incorporated the strengths of the Chinese 2008 and the 7th edition UICC/AJCC staging systems. Chinese 2008 staging should be revised based on the 8th edition UICC/AJCC staging system to make an internationally unified staging system. Therefore, the experts strongly recommended Chinese 2017 staging for NPC should be consistent with the 8th edition UICC/AJCC staging system.